South Africa will introduce a new lenacapavir injection. This twice-yearly shot is for HIV prevention. It will be in select public clinics by April 2026. This marks a big step forward for the nation. It offers a great alternative to daily pills. However, another injectable, cabotegravir, is stalled. It had a four-year head start. The availability of a new HIV…
Tag: PrEP
-
HIV Prevention Injection Changes the Game in Treatment
South Africa will introduce a groundbreaking twice-yearly HIV prevention injection, lenacapavir, in select public clinics by April 2026. This move marks a significant step forward in the nation’s fight against HIV, offering a highly effective and convenient alternative to daily pills. However, this progress comes as another long-acting injectable, cabotegravir (CAB-LA), remains stalled despite having a four-year head start. The…
-
Sakeliga’s NHI Legal Battle for Constiutional Justice
Sakeliga’s NHI Legal Battle has garnered attention. The business lobby group Sakeliga has become the latest organisation to mount a legal challenge against South Africa’s contentious National Health Insurance (NHI) Act. They filed papers at the Pretoria High Court to have it declared unconstitutional and invalid. The focus of Sakeliga’s NHI Legal Battle is to highlight the impracticalities and financial…
-
Lenacapavir for HIV Prevention in South Africa
South Africa is taking a giant step in its fight against HIV. The Department of Health announced plans to make a new, twice-yearly anti-HIV injection available in public clinics. The drug, lenacapavir, represents a potential turning point for HIV prevention. It could significantly curb new infections across the nation. Introducing lenacapavir for HIV prevention could change the landscape of health…
-
Twice-Yearly HIV Jab: Activists Call for Lower Prices
A groundbreaking, twice-yearly injection for HIV prevention is hailed as a potential ‘game-changer’. However, it is at the centre of a fierce debate regarding affordability. Health activists worldwide implore its manufacturer, Gilead Sciences, to prevent a “missed opportunity for achieving equity.” This twice-yearly HIV jab could revolutionise prevention efforts. But that will only occur if it becomes accessible to all.…
-
Global fund affirms commitment to lenacapavir rollout
The Global Fund for HIV, TB, and Malaria has reaffirmed its commitment to rolling out the twice-yearly HIV prevention jab, lenacapavir, in lower-income countries, including South Africa. This initiative will continue with or without the support of the US President’s Emergency Plan for AIDS Relief (Pepfar), which recently encountered funding disruptions during President Donald Trump’s term. According to Global Fund…